The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, evolocumab and alirocumab, are novel lipid-lowering agents that can produce a further substantial reduction in LDL cholesterol in patients who cannot reach target using standard therapy with statins and ezetimibe. This article ...
Considering the consequences of abnormal expression of PCSK9 on other aspects of physiology (e.g., immunity), the difference should be examined in these aspects too. The high conservation of the PCSK9 gene among primates argues in favor of some physiological function of its common allele in ...
Alirocumab Slashed Major Cardiovascular Events: The Effect Was Seen When PCSK9 Was Added to Maximized Statin TherapyAlirocumab Slashed Major Cardiovascular Events: The Effect Was Seen When PCSK9 Was Added to Maximized Statin TherapyJancin, Bruce...
hoarseness, headaches, urinary incontinence, chest pain, and exhaustion and fatigue.1,5,7-9Patients with a chronic cough should be assessed to ascertain its cause and rule out potentially serious medical conditions
Considering the consequences of abnormal expression of PCSK9 on other aspects of physiology (e.g., immunity), the difference should be examined in these aspects too. The high conservation of the PCSK9 gene among primates argues in favor of some physiological function of its common allele in ...
Introduction Proprotein convertase subtilisin kexin type 9 (PCSK9) is a natural inhibitor of the low density lipoprotein receptor (LDLr) and its deficiency confers a high protection against cardiovascular diseases. We previously reported that PCSK9 expression is regulated by nutritional status and ...
doi:10.1016/S0735-1097(18)32980-2Verma, IshaThompson, Paul D.Fernandez, Antonio B.Journal of Clinical Lipidology